Dr Suldan Abdullahi

🔬 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐏𝐞𝐚𝐫𝐥𝐬

𝑨𝒓𝒕𝒊𝒇𝒊𝒄𝒊𝒂𝒍 𝑺𝒘𝒆𝒆𝒕𝒆𝒏𝒆𝒓𝒔 𝒊𝒏 𝑫𝒊𝒂𝒃𝒆𝒕𝒆𝒔: 𝑺𝒖𝒈𝒂𝒓-𝑭𝒓𝒆𝒆, 𝑩𝒖𝒕 𝑵𝒐𝒕 𝑨𝒍𝒘𝒂𝒚𝒔 𝑹𝒊𝒔𝒌-𝑭𝒓𝒆𝒆:

People with diabetes can use artificial sweeteners — but “zero sugar” should not be interpreted as “zero metabolic consequence.”

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐈𝐧𝐭𝐞𝐫𝐩𝐫𝐞𝐭𝐚𝐭𝐢𝐨𝐧

Artificial sweeteners do not usually cause an immediate glucose spike, so they may help patients reduce sugar-sweetened beverages, sweets, and excess calories. However, long-term heavy use may not deliver the metabolic benefit once assumed. Some studies suggest links with altered gut microbiota, impaired glucose tolerance, increased sweet craving, and poorer cardiometabolic outcomes, though causality remains debated.

The WHO 2023 guideline advises against using non-sugar sweeteners as a long-term strategy for weight control or prevention of non-communicable diseases, because sustained benefit is uncertain and observational data raise safety signals. This does not mean occasional use is banned; it means sweeteners should not become the main lifestyle prescription.

𝐓𝐚𝐤𝐞-𝐇𝐨𝐦𝐞 𝐏𝐞𝐚𝐫𝐥𝐬

✅ Occasional use is acceptable in diabetes, especially when replacing sugar-sweetened drinks or desserts.

⚠️ Daily high intake is not ideal, particularly through diet colas, packaged “sugar-free” snacks, biscuits, desserts, and processed foods.

✅ Calorie-free is not consequence-free. The brain, gut microbiome, insulin response, appetite, and food preference may still be affected.

✅ Stevia and monk fruit may be reasonable options, but even these should be used as transition tools, not a license to maintain a high-sweetness diet.

✅ Best strategy: reduce the patient’s overall “sweetness threshold” gradually.

𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐢𝐜𝐞 𝐟𝐨𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬

Use artificial sweeteners in moderation — preferably not more than 1–2 servings per day.

Do not treat “sugar-free” as a free pass. Many sugar-free foods are still high in refined flour, saturated fat, calories, and ultra-processed additives.

Ask patients using CGM or SMBG to check their personal glycemic response, especially after diet drinks, sugar-free sweets, and packaged low-calorie foods.

Prefer water, unsweetened tea, coffee without sugar, lemon water, buttermilk, whole fruits, nuts, and minimally processed foods.

𝐎𝐧𝐞-𝐋𝐢𝐧𝐞 𝐁𝐨𝐭𝐭𝐨𝐦 𝐋𝐢𝐧𝐞

Artificial sweeteners are safe for occasional use in diabetes, but they should be used as a bridge away from sugar — not as a permanent replacement for healthy eating.

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐏𝐞𝐚𝐫𝐥

In diabetes care, the goal is not to replace sugar addiction with “sugar-free” addiction.
The real goal is to reduce sweet craving, improve food quality, and restore metabolic discipline.

Approach to Hypoglycemia :
Reactive vs Fasting Hypoglycemia

Stepwise Clinical Approach to guide theray for CKD MBD .

ANEMIA :
Short Visual guide to Differential Diagnosis

Is there such thing as too much empathy?

The Secret to Caring for the Patient.

sciencedirect.com/science/articl…

Hyperlipidemia Pharmacotherapy:

🩺 Practical Medication Approach to Hyperlipidemia:

🔹 Step 1: Start with Statins (First-Line Therapy):
Best evidence for reducing MI, stroke, and mortality.
Examples:
• Atorvastatin
• Rosuvastatin

📉 Lipid Effects:
• LDL ↓ 30–60%
• TG ↓ mild–moderate
• HDL ↑ slight

✅ Indications:
• Clinical ASCVD
• LDL ≥190 mg/dL
• Diabetes mellitus
• Elevated 10-year ASCVD risk

⚠️ Side Effects:
• Myalgia / myopathy
• Mild transaminitis
• Rare rhabdomyolysis
• Small increased diabetes risk (high-intensity)

💡 Clinical Pearl: Every 1 mmol/L (~39 mg/dL) LDL reductionlowers major vascular events by ~20%.

🔹 Step 2: If LDL Goal Not Reached → Add Ezetimibe!

Ezetimibe:

📉 Lipid Effects:
• LDL ↓ additional 15–20%

✅ Best Use:
• Inadequate response to statin
• Statin intolerance
• Need combination therapy

⚠️ Side Effects:
• Usually well tolerated
• Rare GI upset / mild LFT rise

💡 Adding ezetimibe may equal multiple statin dose escalations.

🔹 Step 3: Very High Risk / Familial Hypercholesterolemia → PCSK9 Inhibitors

Evolocumab
Alirocumab

📉 Lipid Effects:
• LDL ↓ ~50–60%
• Lp(a) ↓ 20–30%
• HDL ↑ mild

✅ Indications:
• ASCVD not at target despite max statin + ezetimibe
• Familial hypercholesterolemia
• Statin intolerance (selected)

⚠️ Side Effects:
• Injection site reactions
• URTI symptoms
• Rare hypersensitivity

🔹 Step 4: Poor Adherence / Preference for Twice-Yearly Dosing:

Inclisiran

📉 Lipid Effects:
• LDL ↓ ~50%

✅ Use:
• Patients needing durable LDL lowering
• Adherence challenges

⚠️ Side Effects:
• Injection site reactions

💡 Dose: Day 0 → 3 months → then every 6 months.

🔹 Step 5: Statin Intolerance / Residual LDL Elevation

Bempedoic acid

📉 Lipid Effects:
• LDL ↓ 15–25%

✅ Use:
• Statin intolerance
• Add-on therapy

⚠️ Side Effects:
• Hyperuricemia / gout
• Tendon injury (rare)
• Mild LFT rise

🔹 Step 6: Hypertriglyceridemia Strategy:

📌 TG 150–499 mg/dL
• Lifestyle first
• Optimize statin
• Consider Icosapent ethyl if high ASCVD risk

📌 TG 500–999 mg/dL
• Prevent pancreatitis
• Consider Fenofibrate ± omega-3

📌 TG ≥1000 mg/dL
🚨 Urgent pancreatitis prevention
• Very low-fat diet
• Stop alcohol
• Control diabetes
• Fibrate-based approach

🔹Simple Clinical Sequence:

1️⃣ Risk stratify patient
2️⃣ Start statin
3️⃣ Recheck lipids in 4–12 weeks
4️⃣ Add ezetimibe if above target
5️⃣ Add PCSK9 / Inclisiran / Bempedoic acid when needed
6️⃣ Treat triglycerides separately when elevated

🔹 Final Message:
Treat cardiovascular risk—not just cholesterol numbers.

Avoid These 10 Mistakes When Prescribing SGLT2 Inhibitors & GLP-1 RAs

1️⃣ Do not treat SGLT2 inhibitors and GLP-1 RAs as “only sugar drugs.”
Their value is now beyond HbA1c. SGLT2 inhibitors are organ-protective drugs for CKD and heart failure, even when HbA1c is not high. GLP-1 RAs also provide cardiovascular, renal, metabolic, and weight-related benefits.

2️⃣ Do not stop SGLT2 inhibitors for the expected early eGFR dip.
A fall in eGFR of around 10–15% after initiation is common and usually reflects beneficial intraglomerular hemodynamic change, not renal toxicity. Up to 30% decline in the first 3 months may be acceptable, but >30% or progressive decline needs evaluation for dehydration, hypotension, excess diuretics, NSAID use, or another renal insult.

3️⃣ Do not overreact to ge***al fungal infections.
Ge***al candidiasis is the commonest adverse effect of SGLT2 inhibitors, especially in obesity, prior fungal infection, and poor hygiene. Most cases can be treated with topical or oral antifungals without stopping the drug. Routine antibiotic or antifungal prophylaxis is not advised.

4️⃣ Never miss euglycemic ketoacidosis.
SGLT2 inhibitor–associated ketoacidosis may occur with glucose not very high. Suspect it in diabetes patients with nausea, vomiting, abdominal pain, breathlessness, fasting, infection, surgery, alcohol excess, ketogenic diet, or insulin omission. Check ketones and acid–base status early.

5️⃣ Teach “sick day rules” clearly.
During acute illness, dehydration, poor oral intake, fasting, or surgery, SGLT2 inhibitors should be temporarily withheld. Patients should maintain fluids, take carbohydrates if possible, continue necessary insulin, and check ketones when unwell.

6️⃣ Stop SGLT2 inhibitors before surgery.
SGLT2 inhibitors should generally be stopped 3 days before surgery and restarted only when the patient is eating normally, hydrated, and clinically stable. This is especially important in patients on insulin, low-carbohydrate diets, or prolonged fasting.

7️⃣ Do not routinely stop GLP-1 RAs before every procedure.
Unlike SGLT2 inhibitors, GLP-1 RAs do not require blanket discontinuation before surgery or endoscopy. Assess risk individually. Hold or modify only in patients with severe nausea, vomiting, known gastroparesis, recent dose escalation, or high aspiration risk. A 24-hour clear liquid diet may be useful in selected cases.

8️⃣ Watch the retina when HbA1c falls rapidly with semaglutide.
Rapid glycemic improvement may transiently worsen diabetic retinopathy in high-risk patients, especially those with pre-proliferative or proliferative retinopathy and very high baseline HbA1c. Retinal screening before initiation and close ophthalmology follow-up are essential.

9️⃣ Do not combine GLP-1 RAs with DPP-4 inhibitors.
This combination adds cost without meaningful extra benefit. When starting a GLP-1 RA, stop sitagliptin, linagliptin, vildagliptin, or other DPP-4 inhibitors.

🔟 Reduce insulin or sulfonylurea when starting GLP-1 RA.
GLP-1 RAs alone have low hypoglycemia risk, but hypoglycemia increases when combined with sulfonylureas, glinides, or insulin. Consider reducing sulfonylurea or basal insulin dose, especially if HbA1c is near target or glucose readings are low.

Practical Bedside Message

SGLT2 inhibitors protect kidney and heart. GLP-1 RAs protect weight, heart, kidney, and metabolism. But both require prescription intelligence.

The commonest preventable errors are: stopping SGLT2 inhibitors for a harmless eGFR dip, missing euglycemic ketoacidosis, poor perioperative planning, ignoring ge***al hygiene counselling, combining GLP-1 RA with DPP-4 inhibitor, and failing to reduce insulin or sulfonylurea.

Take Home;

Prescribe SGLT2 inhibitors and GLP-1 RAs for organ protection, not just HbA1c—but prevent harm by anticipating eGFR dip, ge***al infections, euglycemic DKA, perioperative risks, retinopathy worsening, and hypoglycemia with insulin or sulfonylureas.
Medscape Story -

#❤️🫘 𝐇𝐅 + 𝐂𝐊𝐃
One of the most complex — and most important — overlaps in internal medicine

𝐓𝐡𝐞 𝐤𝐞𝐲 𝐩𝐫𝐢𝐧𝐜𝐢𝐩𝐥𝐞?

➡️ Define the HF phenotype first
➡️ Then anchor every therapeutic decision to the eGFR

Because the same medication may be:
- lifesaving in one renal stage
- and dangerous in another.

….

# 🟠 𝐇𝐅𝐫𝐄𝐅 (𝐄𝐅 ≤𝟒𝟎%) — 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐛𝐲 𝐞𝐆𝐅𝐑

# # 🔸 eGFR